186 related articles for article (PubMed ID: 9519777)
1. Evidence for specific immune response against P210 BCR-ABL in long-term remission CML patients treated with interferon.
Oka T; Sastry KJ; Nehete P; Schapiro SJ; Guo JQ; Talpaz M; Arlinghaus RB
Leukemia; 1998 Feb; 12(2):155-63. PubMed ID: 9519777
[TBL] [Abstract][Full Text] [Related]
2. Molecular monitoring of response to imatinib (Glivec) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remission.
Paschka P; Müller MC; Merx K; Kreil S; Schoch C; Lahaye T; Weisser A; Petzold A; König H; Berger U; Gschaidmeier H; Hehlmann R; Hochhaus A
Leukemia; 2003 Sep; 17(9):1687-94. PubMed ID: 12970765
[TBL] [Abstract][Full Text] [Related]
3. A CD4+ T cell clone selected from a CML patient after donor lymphocyte infusion recognizes BCR-ABL breakpoint peptides but not tumor cells.
Zorn E; Orsini E; Wu CJ; Stein B; Chillemi A; Canning C; Alyea EP; Soiffer RJ; Ritz J
Transplantation; 2001 Apr; 71(8):1131-7. PubMed ID: 11374415
[TBL] [Abstract][Full Text] [Related]
4. Quantification of BCR-ABL transcripts in CML patients in cytogenetic remission after interferon-alpha-based therapy.
Martinelli G; Testoni N; Amabile M; Bonifazi F; De Vivo A; Farabegoli P; Terragna C; Montefusco V; Ottaviani E; Saglio G; Russo D; Baccarani M; Rosti G; Tura S
Bone Marrow Transplant; 2000 Apr; 25(7):729-36. PubMed ID: 10745258
[TBL] [Abstract][Full Text] [Related]
5. Use of alpha-2a-interferon to treat cytogenetic relapse of chronic myeloid leukemia after marrow transplantation.
Higano CS; Chielens D; Raskind W; Bryant E; Flowers ME; Radich J; Clift R; Appelbaum F
Blood; 1997 Oct; 90(7):2549-54. PubMed ID: 9326220
[TBL] [Abstract][Full Text] [Related]
6. Persistence of dormant leukemic progenitors during interferon-induced remission in chronic myelogenous leukemia. Analysis by polymerase chain reaction of individual colonies.
Talpaz M; Estrov Z; Kantarjian H; Ku S; Foteh A; Kurzrock R
J Clin Invest; 1994 Oct; 94(4):1383-9. PubMed ID: 7929813
[TBL] [Abstract][Full Text] [Related]
7. Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha.
Merx K; Müller MC; Kreil S; Lahaye T; Paschka P; Schoch C; Weisser A; Kuhn C; Berger U; Gschaidmeier H; Hehlmann R; Hochhaus A
Leukemia; 2002 Sep; 16(9):1579-83. PubMed ID: 12200666
[TBL] [Abstract][Full Text] [Related]
8. BCR-ABL-positive progenitors in chronic myeloid leukaemia patients in complete cytogenetic remission after treatment with interferon-alpha.
Reiter A; Marley SB; Hochhaus A; Sohal J; Raanani P; Hehlmann R; Gordon MY; Goldman JM; Cross NC
Br J Haematol; 1998 Sep; 102(5):1271-8. PubMed ID: 9753056
[TBL] [Abstract][Full Text] [Related]
9. Conversion of interferon-induced, long-term cytogenetic remissions in chronic myelogenous leukemia to polymerase chain reaction negativity.
Kurzrock R; Estrov Z; Kantarjian H; Talpaz M
J Clin Oncol; 1998 Apr; 16(4):1526-31. PubMed ID: 9552062
[TBL] [Abstract][Full Text] [Related]
10. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia.
Hughes TP; Kaeda J; Branford S; Rudzki Z; Hochhaus A; Hensley ML; Gathmann I; Bolton AE; van Hoomissen IC; Goldman JM; Radich JP;
N Engl J Med; 2003 Oct; 349(15):1423-32. PubMed ID: 14534335
[TBL] [Abstract][Full Text] [Related]
11. Persistence of BCR/ABL mRNA-expressing bone-marrow cells in patients with chronic myelogenous leukemia in complete cytogenetic remission induced by interferon-alpha therapy.
Eberlé F; Toiron Y; Camerlo J; Lafage M; Sainty D; Arnoulet C; Raineri V; Gabert J; Maraninchi D; Mannoni P
Leuk Lymphoma; 1995 Jun; 18(1-2):153-7. PubMed ID: 8580818
[TBL] [Abstract][Full Text] [Related]
12. Efficiency of interphase fluorescence in situ hybridization for BCR/ABL on peripheral blood smears for monitoring of CML patients: a comparison with bone marrow findings.
Akel S; Kolialexi A; Mavrou A; Metaxotou C; Loukopoulos D; Yataganas X
Clin Lab Haematol; 2002 Dec; 24(6):361-7. PubMed ID: 12452817
[TBL] [Abstract][Full Text] [Related]
13. Molecular basis for therapeutic decisions in chronic myeloid leukemia patients after allogeneic bone marrow transplantation.
Román J; Alvarez MA; Torres A
Haematologica; 2000 Oct; 85(10):1072-82. PubMed ID: 11025600
[TBL] [Abstract][Full Text] [Related]
14. BCR/ABL mRNA and the P210(BCR/ABL) protein are downmodulated by interferon-alpha in chronic myeloid leukemia patients.
Pane F; Mostarda I; Selleri C; Salzano R; Raiola AM; Luciano L; Saglio G; Rotoli B; Salvatore F
Blood; 1999 Oct; 94(7):2200-7. PubMed ID: 10498589
[TBL] [Abstract][Full Text] [Related]
15. Does BCR-ABL genomic rearrangement persist in CML patients in complete remission after interferon alpha therapy?
Brizard F; Chomel JC; Veinstein A; Rivet J; Giraud C; Kitzis A; Guilhot F; Brizard A
Leukemia; 1998 Jul; 12(7):1076-80. PubMed ID: 9665193
[TBL] [Abstract][Full Text] [Related]
16. A multivalent bcr-abl fusion peptide vaccination trial in patients with chronic myeloid leukemia.
Cathcart K; Pinilla-Ibarz J; Korontsvit T; Schwartz J; Zakhaleva V; Papadopoulos EB; Scheinberg DA
Blood; 2004 Feb; 103(3):1037-42. PubMed ID: 14504104
[TBL] [Abstract][Full Text] [Related]
17. Monitoring chronic myeloid leukaemia therapy by real-time quantitative PCR in blood is a reliable alternative to bone marrow cytogenetics.
Branford S; Hughes TP; Rudzki Z
Br J Haematol; 1999 Dec; 107(3):587-99. PubMed ID: 10583264
[TBL] [Abstract][Full Text] [Related]
18. [Overexpression of Shp-2 is associated with the unlimited growth and apoptosis resistance of p210 bcr-abl-mediated chronic myeloid leukemia].
Zhu XZ; Yu YZ; Fang YM; Liang Y; Lü QH; Xu RZ
Zhonghua Yi Xue Za Zhi; 2005 Jul; 85(27):1903-6. PubMed ID: 16255985
[TBL] [Abstract][Full Text] [Related]
19. Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre observational trial.
Bocchia M; Gentili S; Abruzzese E; Fanelli A; Iuliano F; Tabilio A; Amabile M; Forconi F; Gozzetti A; Raspadori D; Amadori S; Lauria F
Lancet; 2005 Feb 19-25; 365(9460):657-62. PubMed ID: 15721470
[TBL] [Abstract][Full Text] [Related]
20. Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint fusion peptides generates specific immune responses.
Pinilla-Ibarz J; Cathcart K; Korontsvit T; Soignet S; Bocchia M; Caggiano J; Lai L; Jimenez J; Kolitz J; Scheinberg DA
Blood; 2000 Mar; 95(5):1781-7. PubMed ID: 10688838
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
